Loading clinical trials...
Loading clinical trials...
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Conditions
Interventions
MSC-1
Locations
7
United States
HonorHealth
Scottsdale, Arizona, United States
START MidWest
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center- Monmouth
Middletown, New Jersey, United States
Memorial Sloan Kettering Cancer Center- Westchester
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Start Date
May 21, 2018
Primary Completion Date
September 23, 2019
Completion Date
September 23, 2019
Last Updated
April 5, 2024
NCT05671510
NCT07360314
NCT07403721
NCT03340506
NCT07283705
NCT07438106
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions